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Pulmonary 
Involvement and 
Leptospirosis, 
Greece 
To the Editor: Since the lep-
tospirosis outbreak associated with 
pulmonary hemorrhage in Nicaragua 
in 1995 (1), pulmonary manifesta-
tions of leptospirosis are often rec-
ognized in many countries; reported 
incidence has ranged from 20% to 
70% (2–4). The severe pulmonary 
form of leptospirosis is accompanied 
by pulmonary hemorrhage, which 
directly results in high death rates 
(2,5). In Greece (population 11 mil-
lion), leptospirosis cases in humans 
occur every year, usually from June 
to November (summer and autumn), 
with a peak in August. The annual in-
cidence rate of the disease is 3 cases 
per 1 million population (6). Clinical 
presentation varies from a ﬂ  u-like 
syndrome to Weil disease, which in-
cludes jaundice, renal failure, and 
hemorrhagic complications. Studies 
on leptospirosis in Greece have been 
limited, and no reports have focused 
on pulmonary involvement.
During 1998–2007, we tested 
samples from 650 patients with sus-
pected leptospirosis or hemorrhagic 
fever with renal syndrome (i.e., han-
tavirus infection). Various hospitals of 
northern Greece sent these samples to 
our laboratory (a World Health Orga-
nization Collaborating Center for Ref-
erence and Research on Arboviruses 
and Hemorrhagic Fever) for analysis. 
Because both diseases are endemic to 
Greece and have similar clinical, epi-
demiologic, and seasonal characteris-
tics (7), all samples sent to our labora-
tory for testing either for leptospirosis 
or for hantavirus infection are always 
tested for both (8).
Leptospirosis was conﬁ  rmed for 
123 patients, 10 (8.1%) of whom died 
(Table). For 72 case-patients, paired 
samples were available. A commercial 
ELISA (Leptospira IgG/IgM, Insti-
tute Virion/Serion GmbH, Würzburg, 
Germany) was used to detect immu-
noglobulin (Ig) G and IgM against 
Leptospira spp.. A nested PCR, which 
ampliﬁ   es a 289-bp fragment of the 
16S rDNA gene, was used to detect 
bacterial DNA (9). IgM concentrations 
>20 U/mL indicated acute infection. 
Samples with borderline results were 
tested in parallel with a second sample 
taken from the patient 1 week later. 
IgG concentrations were considered 
only for paired samples, and a case 
was considered as acute leptospiro-
sis when a >4-fold titer rise of IgG, 
or IgG seroconversion, was detected. 
When samples were taken before the 
sixth day of illness, initial diagnosis 
was achieved by PCR. In 6 of 10 fa-
tal cases, leptospirosis was diagnosed 
only by PCR because antibodies were 
not detectable. Epidemiologic and 
clinical information for patients was 
collected from chart review, following 
a protocol approved by the medical 
school review board.
All 123 patients resided in north-
ern Greece. Most (82.1%) were male; 
patients were 6–83 years of age (me-
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dian 51 years). Fifty-two patients were 
farmers; 9 were sewer workers; and 6 
and 2 patients, respectively, reported 
gardening and other recreational ex-
posures before becoming ill. Cases 
occurred in all months; 27% occurred 
in August. Fever, as well as elevated 
levels of serum urea and creatinine, 
occurred in all patients; 55 (44.7%) 
had jaundice, and 46 (37.4%) had 
thrombocytopenia. Weil disease was 
present in 27 (22%). In our case-se-
ries, jaundice appeared to be a com-
mon sign, in contrast to recent studies 
in other countries in which the icteric 
form of the disease was observed in 
only 10% of cases (10). Median age of 
the 10 patients who died was 50 years 
(range 39–78 years). Half of the pa-
tients who died had the icteric form of 
the disease, 4 had the typical signs and 
symptoms of Weil disease, and 1 had 
central nervous system involvement.
Thirty-ﬁ  ve (28.5%) patients had 
pulmonary signs and symptoms, either 
when admitted to the hospital or dur-
ing hospitalization. Eight of these had 
acute respiratory distress syndrome, 6 
had multiple organ dysfunction syn-
drome, and 6 had acute respiratory 
insufﬁ  ciency; the remainder had he-
moptysis and/or dyspnea, according 
clinician notes in the medical charts. 
More than half of the patients had ab-
normal radiographic ﬁ  ndings, mainly 
bilateral bronchoalveolar inﬁ  ltrations. 
Seven (20%) of the 35 case-patients 
with pulmonary involvement died, 
a signiﬁ  cantly higher death rate than 
that for case-patients without pulmo-
nary involvement (3.4%, p<0.01). Re-
spiratory symptoms were recognized 
during the ﬁ  rst phase of the disease, 
as other studies have reported (10). 
We found no signiﬁ  cant difference in 
death rates between males and females 
(p = 0.629).
Pulmonary involvement seems 
to be common and associated with a 
high death rate for patients with severe 
leptospirosis cases in our setting. Cli-
nicians in Greece should include lep-
tospirosis in the differential diagnosis 
of syndromes with associated pulmo-
nary manifestations.  
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Table. Leptospirosis cases and pulmonary involvement, Greece, 1998–2007 
Year  No. cases (no. fatal cases) 
No. cases with pulmonary involvement 
(no. fatal cases) 
1998 12 (0)  0 (0) 
1999 9 (2)  3 (0) 
2000 7 (1)  1 (0) 
2001 11 (0)  1 (0) 
2002 13 (2)  4 (2) 
2003 13 (1)  6 (1) 
2004 20 (3)  10 (3) 
2005 14 (1)  3 (1) 
2006 17 (0)  5 (0) 
2007 7 (0)  2 (0) 
Total 123 (10)  35 (7) 
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